Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Saliby on the Correlation Between Intermediate End Points and OS in Metastatic RCC

July 25th 2024

Renee Saliby, MD, MSc discusses the relationship between intermediate end points and overall survival in metastatic renal cell carcinoma.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Dr Li on Unmet Needs in High-Risk MIBC

July 23rd 2024

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Dr Cigliola on the Background of the SURE-01 Study in MIBC

July 17th 2024

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions

July 15th 2024

IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions.

Dr Garje on the Benefits of Multimodal Treatment in Small Cell Bladder Cancer

July 15th 2024

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCC

July 10th 2024

Brian I. Rini, MD, FASCO, on findings from a biomarker analysis of the KEYNOTE-426 trial of pembrolizumab/axitinib vs sunitinib in renal cell carcinoma.

Neoadjuvant Sacituzumab Govitecan Data Draw Curiosity in Cisplatin-Ineligible MIBC

July 9th 2024

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.

Dr Albigès on the Predictive and Prognostic Utility of KIM-1 in High-Risk RCC

July 8th 2024

Laurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 8th 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Erdafitinib Approaches EU Approval for FGFR3+ Unresectable or Metastatic Urothelial Carcinoma

June 28th 2024

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC

June 27th 2024

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.

Sacituzumab Govitecan/Enfortumab Vedotin ± Pembrolizumab Under Investigation in Metastatic Urothelial Carcinoma

June 26th 2024

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

Perioperative Durvalumab Plus Chemo Meets EFS, OS End Points in MIBC

June 25th 2024

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCC

June 21st 2024

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer

June 21st 2024

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Dr Serzan on the Potential of Botensilimab/Balstilimab to Address Unmet Needs in RCC

June 21st 2024

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Dr Li on Patient Outcomes From the KEYNOTE-057 Trial in BCG-Unresponsive NMIBC

June 20th 2024

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor Burden

June 18th 2024

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.